The Question Beresheet Left on the Moon

On April 11, 2019, Israel watched its Beresheet spacecraft descend toward the Moon.

The spacecraft had already reached lunar orbit. What remained was the most delicate part of the mission, a controlled landing.

During the final descent, technical problems interrupted Beresheet’s braking. Unable to slow sufficiently, the spacecraft crashed into the lunar surface.

The loss of braking explained the immediate cause of the crash, but understanding the failure required examining the chain of events that led to it.

There is a striking parallel in cancer drug development.

Researchers identify a protein believed to contribute to tumor growth and develop a drug designed to inhibit it. Early clinical studies assess safety and dosing and, where feasible, investigate whether the drug produces its intended biological effect.

Suppose these findings justify further development, yet a larger clinical trial fails to demonstrate a meaningful benefit for patients.

What failed?

Perhaps the drug successfully inhibited the protein, but researchers had overestimated how much the cancer depended on that target, and other biological mechanisms continued to sustain the disease.

Perhaps the target mattered primarily in a particular group of patients. Such a possibility may justify further investigation, but it cannot retrospectively turn an unsuccessful trial into a successful one.

The drug might also produce the expected biological effect without generating a response sufficiently large or sustained to translate into meaningful clinical benefit.

Distinguishing among these possibilities matters because a credible patient selection hypothesis may justify another trial, whereas evidence that the broader therapeutic strategy is inadequate may call for a different approach or an end to the program.

There is also an important difference between the two fields. Engineers can sometimes reconstruct a technical failure with considerable precision, while the complexity and adaptability of cancer may leave several explanations unresolved even after a carefully conducted clinical trial.

That makes it especially important to distinguish what the evidence establishes from what it merely suggests.

Beresheet’s journey to lunar orbit was a remarkable achievement, but reaching orbit could not substitute for a successful landing.

Likewise, demonstrating that a drug acts on its intended biological target does not establish that it will improve patients’ lives.

The question after an unsuccessful mission is not simply whether to try again.

It is whether we understand enough about what failed to make the next attempt more than a repetition of the first.